“Bio-Betters” Could Be Good Business, But It’s Not For Genzyme – Termeer
Executive Summary
Follow-on biologics that improve upon the originator drug could be developed into a good business but "that's not where we are choosing to go," Genzyme CEO Henri Termeer said at the Goldman Sachs Healthcare CEOs Unscripted conference Jan. 7
You may also be interested in...
Merck’s Ambitious Plans For Follow-On Biologics
Merck outlined ambitious plans for launching and growing a follow-on biologics business during its annual business briefing Dec. 9
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.